Drugs / ASP2138
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07024615 | Oct 2025 → Jan 2028 expected | pancreatic ductal adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05365581 | Jun 2022 → May 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07673887 | Jun 2026 → Feb 2031 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Astellas Pharma Global Development, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2138 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07673887 ↗ |
| Route | Intravenous | “ASP2138 is either given through a vein (intravenous infusion) or just under the skin (subcutaneous injection).” NCT05365581 ↗ |
| Route | Subcutaneous | “ASP2138 is either given through a vein (intravenous infusion) or just under the skin (subcutaneous injection).” NCT05365581 ↗ |